Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

Kan Kikuchi(Japanese Society for Dialysis Therapy), Tadao Akizawa(Showa University), Hidetomo Nakamoto(Renal Association), Oota Yoshihiro(Nagoya Memorial Hospital), Ken Sakai(Japanese Society for Dialysis Therapy), Masaomi Nangaku(The University of Tokyo), Toshio Shinoda(Renal Association), Norio Hanafusa(Tokyo Women's Medical University Hospital), Munekazu Ryuzaki(Saiseikai Central Hospital), Tomoyuki Yamakawa(Toho University), Ryoichi Ando, Yoshihiko Kanno
Renal Replacement Therapy
October 21, 2021
10.1186/s41100-021-00378-0
Cited by 61

Related Papers

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|921
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
|Kidney International|2016|474
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)
|Therapeutic Apheresis and Dialysis|2015|425